Manufacturing & Sterility

Content Uniformity

What a definition is not

A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.

A finished-product test verifying that individual dosage units of a batch — tablets, capsules, or other discrete units — contain an amount of active ingredient within a narrow range of the labelled claim, assessed under a two-stage acceptance value procedure that evaluates both the mean and the variability of individual unit assay results.

Content uniformity is distinguished from assay: assay confirms the average potency of a composite sample meets specification, while content uniformity confirms that individual units do not deviate excessively from that average, which matters most for low-dose, high-potency, or narrow therapeutic index products.

The stage-1 sample (typically 10 units) is tested first; if it does not meet the acceptance value criterion outright, a larger stage-2 sample is tested and the combined data re-evaluated, rather than the batch failing on the smaller sample alone.

Persistent or recurring content uniformity failures are typically traced back to blend uniformity, segregation during transfer or compression, or fill-weight variability, making it a key downstream signal for upstream process robustness.

KEY POINTS
  • Distinct from assay: evaluates unit-to-unit variability, not just the batch average.
  • Uses a two-stage acceptance value sampling and calculation procedure.
  • Most critical for low-dose, high-potency, and narrow-therapeutic-index products.
  • Failures are commonly traced upstream to blend uniformity or fill-weight variability.
REGULATORY BASIS

USP <905>; Ph. Eur. 2.9.40

Frequently asked questions

What is Content Uniformity?

A finished-product test verifying that individual dosage units of a batch — tablets, capsules, or other discrete units — contain an amount of active ingredient within a narrow range of the labelled claim, assessed under a two-stage acceptance value procedure that evaluates both the mean and the variability of individual unit assay results.

Which regulations cover Content Uniformity?

USP <905>; Ph. Eur. 2.9.40